At the same time, GSTZ1 re-expression increases the sensitivity of HCC cells to sorafenib treatment, suggesting a negative regulatory role for GSTZ1 in resistance to sorafenib (Wang Q et al., 2021). This evidence concerns the gene GSTZ1 and hepatocellular carcinoma.